Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

Provided By Globe Newswire

Last update: Nov 22, 2022

Lucira’s COVID-19 & Flu Test performed comparably in a head-to-head comparison study with highly sensitive lab-based PCR tests

EMERYVILLE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for its Lucira COVID-19 & Flu Test, for point-of-care use. The Lucira COVID-19 & Flu Test is a molecular test that performed comparably to highly sensitive lab-based PCR assays in clinical trials. This combination test is the first in a pipeline of other multiple assay tests that leverage Lucira technology platform’s ability to multiplex from a single sample. The easy-to-use test delivers results between 11 and 30 minutes from one shallow nasal swab. The Lucira COVID-19 & Flu Test is available for use in CLIA-waived settings and can be purchased online at: www.lucirahealth.com, or email sales@lucirahealth.com for bulk orders.